Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 16/20 | 0.69 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.69 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 2/20 | 0.38 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7625002 | 0.93 | PTPN1 (0.67) | PTPN1PTPN2EPHX2PPARGBTN3A1 | |
| SCHEMBL7626492 | 0.90 | PTPN1 (0.71) | PTPN1PTPN2EPHX2PPARGCHRM1 | |
| SCHEMBL7622217 | 0.88 | PTPN1 (0.67) | PTPN1PTPN2EPHX2PPARGCHRM1 | |
| SCHEMBL7623925 | 0.83 | PTPN1 (0.68) | PTPN1PTPN2EPHX2PPARGCHRM1 | |
| SCHEMBL7161699 | 0.83 | PTPN1 (1.00) | PTPN1PTPN2 | |
| SCHEMBL21067870 | 0.83 | PTPN1 (1.00) | PTPN1PTPN2 | |
| SCHEMBL7620481 | 0.81 | PTPN1 (0.68) | PTPN1PTPN2EPHX2PPARGCHRM1 | |
| SCHEMBL6846457 | 0.81 | PTPN1 (0.74) | PTPN1PTPN2EPHX2PPARGCHRM1 | |
| SCHEMBL7621370 | 0.81 | PTPN1 (0.65) | PTPN1PTPN2EPHX2PPARGCHRM1 | |
| SCHEMBL7165170 | 0.79 | PTPN1 (0.74) | PTPN1PTPN2EPHX2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6486142-B2 | A,A-DIFLUOROBENZYLPHOSPHONIC ACID DERIVATIVES | MERCK FROSST CANADA & CO. (CA) | 2002-11-26 | — | — | US | disclosed |
| US-20020058644-A1 | Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B) | MERCK FROSST CANADA LTD. (CA) | 2002-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058644-A1 | Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B) | PPM1B, PTPRO, PTPA | PTPN1 13/4885PTPN2 32/4885EPHX2 2127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.